)
Visual
test
Laurus Labs
Laurus Labs (LAURUSLABS) investor relations material
Laurus Labs Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary23 Jan, 2026
Executive summary
Achieved strong operational and financial performance in Q3 and 9M FY2026, with consolidated revenue for Q3 at ₹1,778.29 crore and 9M revenue at ₹5,044.48 crore, driven by growth in generics and CDMO segments.
Net profit after tax for Q3 was ₹251.88 crore, with 9M net profit at ₹610 crore, up 388% year-over-year.
Continued investments in peptide, ADC, and gene therapy infrastructure, and expanded leadership in ARV segment.
Significant CAPEX investment, representing 15% of sales, to expand manufacturing and niche capabilities.
Key investments made in Laurus Bio and KRKA Pharma joint ventures during the quarter.
Financial highlights
Q3 FY2026 revenue: ₹1,778 crore, up 26% year-over-year; 9M FY26 revenue: ₹5,001 crore, up 30% year-over-year.
Gross margin for Q3: 60.9%; nine-month gross margin: 60.1%, up 4.3 percentage points.
Q3 EBITDA: ₹485 crore (27% margin); 9M EBITDA: ₹1,303 crore (26.1% margin), up 104% year-over-year.
Net profit for 9M: ₹610 crore, up 388% year-over-year; Q3 PAT: ₹252 crore, up 174% year-over-year.
Net debt-to-EBITDA improved to 1.2x; ROCE at 18.5%.
Outlook and guidance
Confident in delivering healthy operational growth for FY2026, supported by robust CDMO outlook and stable ARV business.
Gross margins expected to remain around 60% for the coming quarter and next financial year.
CapEx for FY2026 and FY2027 projected at over ₹1,000 crore each year.
The company is evaluating the impact of new Indian labour codes effective November 2025.
Laurus Bio, KRKA investment impact
Laurus Synthesis demerger: expected benefits
Q3 consolidated vs standalone profit drivers
CDMO FY27 growth drivers
Rationale for avoiding mAb/sterile manufacturing
500-acre greenfield project timeline
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and robust acquisitions. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebNVDA
AI-driven digital twins and real-time simulation will transform engineering and manufacturing. - 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position. - 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy.
Next Laurus Labs earnings date
Q4 25/2624 Apr, 2026
Laurus Labs
Next Laurus Labs earnings date
Q4 25/2624 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Laurus Labs Limited, a pharmaceutical company, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and formulations in India. It involves in the development of antiviral APIs; generic APIs for hepatitis C and HIV Darunavir tablets; and oncology BCS class II drugs. The company also develops and commercializes single super specialty products comprising linezolid and formoterol. The company was incorporated in 2005 and is based in Hyderabad, India.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage